Similar articles for PMID: 29129093

Year	Number of Results
2013	2
2014	6
2015	15
2016	16
2017	21
2018	24
2019	19
2020	14
2021	18
2022	8
2023	4
2024	0

1

Systemic therapy for esophagogastric cancer: immune checkpoint inhibition.

Lyons TG, Ku GY. Lyons TG, et al. Chin Clin Oncol. 2017 Oct;6(5):53. doi: 10.21037/cco.2017.09.03. Chin Clin Oncol. 2017. PMID: 29129093 Free article.

2

Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.

Herzberg B, Campo MJ, Gainor JF. Herzberg B, et al. Oncologist. 2017 Jan;22(1):81-88. doi: 10.1634/theoncologist.2016-0189. Epub 2016 Aug 17. Oncologist. 2017. PMID: 27534574 Free PMC article. Review.

3

Immune Checkpoint Blockade in Breast Cancer Therapy.

Bu X, Yao Y, Li X. Bu X, et al. Adv Exp Med Biol. 2017;1026:383-402. doi: 10.1007/978-981-10-6020-5_18. Adv Exp Med Biol. 2017. PMID: 29282694 Review.

4

Immune checkpoint inhibitors in small cell lung cancer.

Pakkala S, Owonikoko TK. Pakkala S, et al. J Thorac Dis. 2018 Feb;10(Suppl 3):S460-S467. doi: 10.21037/jtd.2017.12.51. J Thorac Dis. 2018. PMID: 29593891 Free PMC article. Review.

5

Checkpoint blocking antibodies in cancer immunotherapy.

Kyi C, Postow MA. Kyi C, et al. FEBS Lett. 2014 Jan 21;588(2):368-76. doi: 10.1016/j.febslet.2013.10.015. Epub 2013 Oct 23. FEBS Lett. 2014. PMID: 24161671 Free article. Review.

6

Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma.

Schlößer HA, Drebber U, Kloth M, Thelen M, Rothschild SI, Haase S, Garcia-Marquez M, Wennhold K, Berlth F, Urbanski A, Alakus H, Schauss A, Shimabukuro-Vornhagen A, Theurich S, Warnecke-Ebertz U, Stippel DL, Zippelius A, Büttner R, Hallek M, Hölscher AH, Zander T, Mönig SP, von Bergwelt-Baildon M. Schlößer HA, et al. Oncoimmunology. 2015 Nov 9;5(5):e1100789. doi: 10.1080/2162402X.2015.1100789. eCollection 2016 May. Oncoimmunology. 2015. PMID: 27467911 Free PMC article.

7

Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.

McArthur HL, Page DB. McArthur HL, et al. Clin Adv Hematol Oncol. 2016 Nov;14(11):922-933. Clin Adv Hematol Oncol. 2016. PMID: 27930644 Review.

8

Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.

Marginean EC, Melosky B. Marginean EC, et al. Arch Pathol Lab Med. 2018 Jan;142(1):26-34. doi: 10.5858/arpa.2017-0041-RA. Epub 2017 Nov 9. Arch Pathol Lab Med. 2018. PMID: 29120224 Free article. Review.

9

Immune checkpoint inhibition in ovarian cancer.

Hamanishi J, Mandai M, Konishi I. Hamanishi J, et al. Int Immunol. 2016 Jul;28(7):339-48. doi: 10.1093/intimm/dxw020. Epub 2016 Apr 7. Int Immunol. 2016. PMID: 27055470 Review.

10

[Development of immune checkpoint inhibitors].

Kitano S. Kitano S. Rinsho Ketsueki. 2017;58(8):966-976. doi: 10.11406/rinketsu.58.966. Rinsho Ketsueki. 2017. PMID: 28883282 Japanese.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

139 results

Results by year